Logo

Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Share this
Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Shots:
  • The data includes results from P-III extension studies of OPERA I- OPERA II and ORATORIO assessing Ocrevus in patients with RMS and PPMS earlier treated with IFN beta-1α or PBO respectively
  • Ocrevus resulted in suppression of relapse and MRI disease (16.1% vs 21.3% @5yrs.)- suppression of T1-gadolinium enhancing (T1-Gd+) lesions (0.004 vs 0.49 @3yrs.) in RMS; In PPMS patients DP reduced to 96% and upper limb DP is 13.4% as measured by the nine-hole peg test (9-HPT) @24 wks.
  • Additionally- results from P-III CHORDS for RRMS showed no relapse- T1-Gd+ lesion MRI activity and N/E T2 lesion MRI activity with no 24-wks CDP @48wks. Ocrevus is approved in 68 countries including EU- Australia& Switzerland with awaited marketing approval in 20 countries
/article Ref: Roche | Image: Roche Diagnostics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions